99 related articles for article (PubMed ID: 32072763)
1. Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Yokote K; Sano M; Tsumiyama I; Keefe D
Diabetes Obes Metab; 2020 Jul; 22(7):1102-1110. PubMed ID: 32072763
[TBL] [Abstract][Full Text] [Related]
2. Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Bays HE; Kozlovski P; Shao Q; Proot P; Keefe D
Obesity (Silver Spring); 2020 May; 28(5):870-881. PubMed ID: 32187881
[TBL] [Abstract][Full Text] [Related]
3. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
He YL; Haynes W; Meyers CD; Amer A; Zhang Y; Mahling P; Mendonza AE; Ma S; Chutkow W; Bachman E
Diabetes Obes Metab; 2019 Jun; 21(6):1311-1321. PubMed ID: 30724002
[TBL] [Abstract][Full Text] [Related]
4. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
de Boer RA; Núñez J; Kozlovski P; Wang Y; Proot P; Keefe D
Br J Clin Pharmacol; 2020 Jul; 86(7):1346-1356. PubMed ID: 32068914
[TBL] [Abstract][Full Text] [Related]
5. Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial.
Tan S; Ignatenko S; Wagner F; Dokras A; Seufert J; Zwanziger D; Dunschen K; Zakaria M; Huseinovic N; Basson CT; Mahling P; Fuhrer D; Hinder M
Diabetes Obes Metab; 2021 Nov; 23(11):2595-2599. PubMed ID: 34263971
[TBL] [Abstract][Full Text] [Related]
6. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.
Harrison SA; Manghi FP; Smith WB; Alpenidze D; Aizenberg D; Klarenbeek N; Chen CY; Zuckerman E; Ravussin E; Charatcharoenwitthaya P; Cheng PN; Katchman H; Klein S; Ben-Ari Z; Mendonza AE; Zhang Y; Martic M; Ma S; Kao S; Tanner S; Pachori A; Badman MK; He Y; Ukomadu C; Sicard E
Nat Med; 2022 Jul; 28(7):1432-1438. PubMed ID: 35725922
[TBL] [Abstract][Full Text] [Related]
7. Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial.
He Y; Pachori A; Chen P; Ma S; Mendonza AE; Amer A; Marbury TC; Hinder M
Diabetes Obes Metab; 2021 May; 23(5):1182-1190. PubMed ID: 33512754
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
[TBL] [Abstract][Full Text] [Related]
9. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study.
Shirai K; Fujita T; Tanaka M; Fujii Y; Shimomasuda M; Sakai S; Samukawa Y
Adv Ther; 2019 Jan; 36(1):86-100. PubMed ID: 30535651
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials.
Zaki AM; Abo-Elnour DE; Abdalla YE; Hassan RY; Salama MK; Elboraay T; Abdelhaleem IA
Diabetes Metab Syndr; 2022 Nov; 16(11):102657. PubMed ID: 36335885
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Lundkvist P; Sjöström CD; Amini S; Pereira MJ; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
[TBL] [Abstract][Full Text] [Related]
14. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
15. Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial.
He Y; Schofield J; Mahling P; Mendonza AE; Hinder M
Clin Pharmacol Ther; 2020 Nov; 108(5):995-1002. PubMed ID: 32236953
[TBL] [Abstract][Full Text] [Related]
16. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
17. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
[TBL] [Abstract][Full Text] [Related]
19. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
[TBL] [Abstract][Full Text] [Related]
20. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
